Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6/2 transgenic mice

Journal of Comparative Neurology

Volumn 449, Issue 3, 2002, Pages 241-269

  Meade, Christopher A ^a   Deng, Yun Ping ^a   Fusco, Francesca R ^b   Del Mar, Nobel ^a   Hersch, Steven ^c   Goldowitz, Dan ^a   Reiner, Anton ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Animal disease models; Confocal microscopy; Huntington's disease; Immunohistochemistry; Light microscopy; Ubiquitin

Indexed keywords

CALBINDIN; PARVALBUMIN; SOMATOSTATIN;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; BRAIN CORTEX; CELL NUCLEUS INCLUSION BODY; CELLULAR DISTRIBUTION; CHOLINERGIC NERVE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; GENOTYPE; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; INTERNEURON; LEARNING DISORDER; MOTOR DYSFUNCTION; MOUSE; NEURONAL INTRANUCLEAR INCLUSION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; STRIATE CORTEX; TRANSGENE; TRANSGENIC MOUSE;

AGING; ANIMALS; CELL NUCLEUS; CEREBRAL CORTEX; CORPUS STRIATUM; HUMANS; INCLUSION BODIES; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; TISSUE DISTRIBUTION; UBIQUITIN;

EID: 0037194221     PISSN: 00219967     EISSN: None     Source Type: Journal    
DOI: 10.1002/cne.10295     Document Type: Article

References (146)

1. Isolation and characterization of a novel gene with differential expression in benign and malignant human breast tumours
2. Genetics and molecular biology of Huntington's disease
3. Striatal and nigral neuron subpopulations in rigid Huntington's disease: Implications for the functional anatomy of chorea and rigidity-akinesia
4. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease
5. Preferential loss of striatoexternal pallidal projection neurons in presymptomatic Huntington's disease
6. Structure and expression of the Huntington's disease gene: Evidence against simple inactivation due to an expanded CAG repeat
7. Extensive cooccurrence of substance P and dynorphin in striatal projection neurons: An evolutionarily conserved feature of basal ganglia organization
8. Interneuron migration from basal forebrain to neocortex: Dependence on Dlx genes
9. Mutations of the homeobox genes Dlx-1 and Dlx-2 disrupt the striatal subventricular zone and differentiation of late born striatal neurons
10. Immunocytochemical localization of ubiquitin in inclusion body myositis allows its light-microscopic distinction from polymyositis
11. The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin
12. Expanded glutamines and neurodegeneration - A gain of insight
13. Somatostatin and neuropeptide Y concentrations in pathologically graded cases of Huntington's disease
14. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: Correlation between the density of inclusions and IT15 CAG triplet repeat length
15. cFos immunoreactivity is enhanced with biotin amplification
16. The identification of a functional nuclear localization signal in the Huntington disease protein
17. Expression of normal and mutant huntingtin in the developing brain
18. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice
19. Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays
20. Catalyzed reporter deposition, a novel method of signal amplification. II. Application to membrane immunoassays
21. Huntington's chorea. Historical, clinical and laboratory synopsis
22. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation
23. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene
24. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease
25. Evidence for the preferential localization of glutamate receptor-1 subunits of AMPA receptors to the dendritic spines of medium spiny neurons in rat striatum
26. Parvalbumin-containing GABAergic interneurons in the rat neostriatum
27. Degeneration of pyramidal projection neurons in Huntington's disease cortex
28. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1
29. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice
30. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation
31. Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions?
32. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease
33. Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice
34. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons
35. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain
36. Nuclear targeting sequences - A consensus?
37. Analysis of the subcellular localization of huntingtin with a set of rabbit polyclonal antibodies in cultured mammalian cells of neuronal origin: Comparison with the distribution of huntingtin in Huntington's disease autopsy brain
38. Inactivation of the mouse Huntington's disease gene homolog Hdh
39. Selective sparing of a class of striatal neurons in Huntington's disease
40. Topography of enkephalin, substance P and acetylcholinesterase staining in Huntington's disease striatum
41. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease
42. Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum
43. Parvalbumin-immunoreactive neurons in the cerebral cortex and striatum in Huntington's disease
44. Polyglutamine expansions: Proteolysis, chaperones, and the dangers of promiscuity
45. Relative survival of striatal projection neurons and interneurons after intrastriatal injection of quinolinic acid in rats
46. Calretinin is largely localized to a unique population of striatal interneurons in rats
47. Colocalization of somatostatin, neuropeptide Y, neuronal nitric oxide synthase and NADPH-diaphorase in striatal interneurons in rats
48. Age-dependent differences in survival of striatal somatostatin-NPY-NADPH-diaphorase-containing interneurons versus striatal projection neurons after intrastriatal injection of quinolinic acid in rats
49. Relative resistance of striatal neurons containing calbindin or parvalbumin to quinolinic acid-mediated excitotoxicity compared to other striatal neuron types
50. Cellular localization of huntingtin in striatal and cortical neurons in rats: Lack of correlation with neuronal vulnerability in Huntington's disease
51. Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: An in situ hybridization histochemistry and fluorescent retrograde tracing study
52. Synthetic peptides as nuclear localization signals
53. Quantitative neuropathological changes in presymptomatic Huntington's disease
54. Differential distribution of the normal and mutated forms of huntingtin in the human brain
55. Neuronal distribution of intranuclear inclusions in Huntington's disease with adult onset
56. Quantification without pontification: Choosing a method for counting objects in sectioned tissues
57. Trinucleotide instability: A repeating theme in human inherited disorders
58. Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with antifusion protein antibodies
59. Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology
60. The influence of huntingtin protein size on nuclear localization and cellular toxicity
61. The fatal attraction of polyglutamine-containing proteins
62. Parvalbumin immunoreactive neurons resist degeneration in Huntington's disease striatum
63. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease
64. A YAC mouse model for Huntingon's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration
65. Spinocerebellar ataxia type 7 (SCA7): A neurodegenerative disorder with neuronal intranuclear inclusions
66. Characterization and localization of the Huntington disease gene product
67. Amyloid formation by mutant huntingtin: Threshold, progressivity and recruitment of normal polyglutamine proteins
68. A simple and sensitive antigen retrieval method for free-floating and slide-mounted tissue sections
69. Mechanisms of striatal pattern formation: Conservation of mammalian compartmentalization
70. Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: Relevance to diseases of the nervous system
71. Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin
72. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells
73. Neuronal intranuclear inclusions in polyglutamine diseases: Nuclear weapons or nuclear fallout?
74. Parvalbumin-immunoreactive neurons in the rat neostriatum: A light and electron microscopic study
75. Calbindin D28K as a marker for the degeneration of the striatonigral pathway in Huntington's disease
76. Ataxin-1 nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice
77. Intranuclear inclusions in subtypes of striatal neurons in Huntington's disease transgenic mice
78. Huntingtin immunoreactivity in the rat neostriatum: Differential accumulation in projection and interneurons
79. Huntington aggregates may not predict neuronal death in Huntington's disease
80. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease
81. Huntington's disease gene: Regional and cellular expression in brain of normal and affected individuals
82. The medial ganglionic eminence gives rise to a population of early neurons in the developing cerebral cortex
83. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity
84. Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats
85. Huntington's disease gene (IT15) is widely expressed in human and rat tissues
86. Neurological abnormalities in a knock-in mouse model of Huntington's disease
87. Expanding our understanding of polyglutamine diseases through mouse models
88. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation
89. A cellular model that recapitulates major pathogenic steps of Huntington's disease
90. Pathological mechanisms in Huntington's disease and other polyglutamine expansion diseases
91. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease
92. Distribution of inclusions in neuronal nuclei and dystrophic neurites in Huntington disease brain
93. Significant loss of pyramidal neurons in the angular gyrus of patients with Huntington's disease
94. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice
95. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates
96. Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease
97. Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease
98. Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington's disease mutation
99. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation
100. Homozygote for Huntington disease
101. A molecular investigation of true dominance in Huntington's disease
102. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes
103. Assembly in vitro of nuclei active in nuclear protein transport: ATP is required for nucleoplasmin accumulation
104. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease
105. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3
106. Normal and expanded Huntington's disease gene alleles produce distinguishable proteins due to translation across the CAG repeat
107. Differential expression of normal and mutant Huntington's disease gene alleles
108. Glutamine repeats and neurodegenerative diseases: Molecular aspects
109. Glutamine repeats as polar zippers: Their possible role in inherited neurodegenerative diseases
110. Recent advances on the pathogenesis of Huntington's disease
111. Evidence for a recruitment and sequestration mechanism in Huntington's disease
112. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA
113. Recent advances in understanding the pathogenesis of Huntington's disease
114. Differential loss of striatal projection neurons in Huntington disease
115. Brain GABA levels in asymptomatic Huntington's disease
116. Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients
117. Neuropathology of Huntington's chorea
118. Intranuclear neuronal inclusions: A common pathogenic mechanism for glutamine-repeat neurodegenerative diseases?
119. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis
120. Huntingtin localization in brains of normal and Huntington's disease patients
121. Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease
122. Early and progressive accumulation of reactive microglia in the Huntington disease brain
123. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions
124. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin
125. Neurobiology of Huntington's disease
126. Widespread expression of Huntington's disease gene (IT15) protein product
127. A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice
128. Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein
129. Nuclear inclusions in glutamine repeat disorders: Are they pernicious, coincidental, or beneficial?
130. Evidence for neuronal degeneration and dendritic plasticity in cortical pyramidal neurons of Huntington's disease: A quantitative Golgi study
131. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies
132. The cortical lesion of Huntington's disease: Further neurochemical characterization, and reproduction of some of the histological and neurochemical features by N-methyl-D-aspartate lesions of rat cortex
133. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse
134. Ultrastructure of neurofibrillary tangles in Steele-Richardson-Olszewski syndrome
135. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
136. Full length huntingtin is not detected in intranuclear inclusions in Huntington's disease brain
137. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form
138. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease
139. Huntington disease
140. Neuropathological classification of Huntington's disease
141. Of molecular interactions, mice and mechanisms: New insights into Huntington's disease
142. Homozygotes for Huntington's disease
143. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice
144. Young neurons from medial ganglionic eminence disperse in adult and embryonic brain
145. tRNA transport from the nucleus in a eukaryotic cell: Carrier-mediated translocation process
146. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue